Immucell Revenue Growth Rates (ICCC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immucell Corporation  (NASDAQ: ICCC)
 

ICCC's Revenue Growth by Quarter and Year

Immucell's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ICCC/growth
https://api.csimarket.com/api/v1/companies/ICCC/fundamentals
https://api.csimarket.com/api/v1/companies/ICCC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ICCC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8.04
2nd Quarter June 7.19
1st Quarter March 9.66
FY 24.89

ICCCs Annual Revenue
Immucell's Revenue in the fiscal year 2025 $ 27.45 millions
Immucell's Revenue in the fiscal year 2024 $ 26.49 millions
Immucell's Revenue in the fiscal year 2023 $ 17.47 millions
Immucell's Revenue in the fiscal year 2022 $ 18.57 millions
Immucell's Revenue in the fiscal year 2021 $ 19.24 millions




ICCC Revenue third quarter 2026 Y/Y Growth Comment
Immucell Corporation achieved in the third quarter 2026, above Company average Revenue rise of 50% year on year, to $ 8.04 millions.

Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Immucell Corporation' s Revenue jump of 50% ranks overall at the positon no. 1564 in the third quarter 2026.


ICCC Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 50 %
2nd Quarter June 11.65 %
1st Quarter March 19.7 %
FY   -

Financial Statements
Immucell's third quarter 2026 Revenue $ 8.04 millions ICCC's Income Statement
Immucell's third quarter 2025 Revenue $ 5.36 millions Quarterly ICCC's Income Statement


ICCC Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 11.82 %
2nd Quarter June -25.57 %
1st Quarter March 27.61 %
FY (Year on Year)   -


Back to ICCC Growth rate Comparisons >> Back to ICCC Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #261
Overall #1564

Revenue Y/Y Growth Statistics
High Average Low
82.66 % 16.09 % -42.55 %
(Dec 31 2024)   (Jun 30 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #261
Overall #1564
Revenue Y/Y Growth Statistics
High Average Low
82.66 % 16.09 % -42.55 %
(Dec 31 2024)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Immucell's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
122.27 % 6.7 % -50.63 %
(Dec 31 2019)  


ICCC's III. Quarter Q/Q Revenue Comment
Immucell Corporation achieved in the III. Quarter 2026 above company average sequential Revenue rise of 11.82%, to $ 8.04 millions, from $7.19 millions in the second quarter.
ICCC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Immucell's Revenue growth quarter on quarter, overall rank is 3364.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #11
Healthcare Sector #468
Overall #3364
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #11
Healthcare Sector #468
Overall #3364
Revenue Q/Q Growth Statistics
High Average Low
122.27 % 6.7 % -50.63 %
(Dec 31 2019)  


ICCC's III. Quarter Q/Q Revenue Comment
Immucell Corporation achieved in the III. Quarter 2026 above company average sequential Revenue rise of 11.82%, to $ 8.04 millions, from $7.19 millions in the second quarter.
ICCC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Immucell's Revenue growth quarter on quarter, overall rank is 3364.


Immucell's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 29.78
Y / Y Revenue Growth (TTM) 1.01 %
Year on Year Revenue Growth Overall Ranking # 477
Seqeuential Revenue Change (TTM) 2.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 2156


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immucell's cumulative twelve months Revenue were $ 30 millions, company would post below average annual Revenue growth of 2.55% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immucell's Revenue growth from the 7.19% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 231 to 477.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 114
Overall # 477

Revenue TTM Y/Y Growth Statistics
High Average Low
57.2 %
 17.73 %
-25.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 321
S&P 500 # 2156
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immucell's cumulative twelve months Revenue were $ 30 millions, company would post below average annual Revenue growth of -25.7% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immucell's Revenue growth from the 7.19% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 231 to 477.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 114
Overall # 477

Revenue TTM Y/Y Growth Statistics
High Average Low
57.2 %
17.73 %
-25.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 321
S&P 500 # 2156




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ICCC's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions


About Immucell Revenue Growth Rates (ICCC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Immucell Corp (CIK 811641).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-036588
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Immucell Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.